Program
inaticabtagene autoleucel
Also written as “single dose of CNCT19”, “Inaticabtagene Autoleucel Injection” and “Inaticabtagene autoleucel Injection”.
Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma · Anemia, Hemolytic, Autoimmune · Burkitt Lymphoma · Purpura, Thrombocytopenic, Idiopathic · Lupus Erythematosus, Systemic, led by Juventas Cell Therapy.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Juventas Cell Therapy | 86 open or running | phase 2since Oct 8, 2020 | Jan 11, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 11, 2020First studies: 2 phase 1 studiesFirst studyNCT04232826, NCT04230473
- Oct 8, 2020Phase 2 study in Lymphoma, Non-HodgkinNCT04586478 · 60 planned · China
- Dec 9, 2020Phase 2 study in RecurrenceNCT04684147 · 100 planned · China
- Dec 5, 2022Phase 2 study in Burkitt LymphomaNCT05667506 · 47 planned · China
- Mar 4, 2024Early phase 1 study in Lupus Erythematosus, SystemicNCT06316791 · 24 planned · China
- Feb 6, 2025Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT06826430 · 12 planned · China
- Jul 21, 2025Phase 1 study in Anemia, Hemolytic, AutoimmuneNCT07091370 · 12 planned
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07091370Anemia, Hemolytic, Autoimmune | 1 | Not yet recruiting | Sep 30, 2026 | 12 |
| NCT06826430Purpura, Thrombocytopenic, Idiopathic · China | 1 | Recruiting | Mar 31, 2026 | 12 |
| NCT06316791Lupus Erythematosus, Systemic · China | Early 1 | Recruiting | Dec 13, 2025 | 24 |
| NCT05667506Burkitt Lymphoma · China | 2 | Recruiting | May 30, 2025 | 47 |
| NCT04684147Recurrence · China | 2 | Recruiting | Sep 22, 2022 | 100 |
| NCT04586478Lymphoma, Non-Hodgkin · China | 2 | Recruiting | Mar 30, 2024 | 60 |
| NCT04232826Diffuse Non-Hodgkin Lymphoma · China | 1 | Completed | Jan 1, 2021 | 9 |
| NCT04230473Recurrence · China | 1 | Completed | Dec 1, 2020 | 10 |
How it is read
Names in the registry
- “single dose of CNCT19”, 6 entries
- “Inaticabtagene Autoleucel Injection”, 1 entry
- “Inaticabtagene autoleucel Injection”, 1 entry
Conditions, from the studies’ own filings
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 2 studies
- Anemia, Hemolytic, Autoimmune, 1 study
- Burkitt Lymphoma, 1 study
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.